<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619969</url>
  </required_header>
  <id_info>
    <org_study_id>2012/025/E</org_study_id>
    <nct_id>NCT01619969</nct_id>
  </id_info>
  <brief_title>Celgosivir as a Treatment Against Dengue</brief_title>
  <acronym>CELADEN</acronym>
  <official_title>Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke-NUS Graduate Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, Double-Blind, Placebo-Controlled, Phase 1b Clinical Study to Evaluate
      the Activity, Pharmacokinetics, Safety and Tolerability of Celgosivir in Adults with
      Confirmed Dengue Fever.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with confirmed dengue fever who meet all inclusion and exclusion criteria will be
      enrolled and admitted to the Investigational Medicine Unit. Patients will be randomized 1:1
      to celgosivir or placebo. Capsules of placebo or celgosivir will be administered for 5 days.
      While in hospital, daily clinical exams will be conducted, and blood samples will be
      collected for viral load, quantitative NS1, hematology, clinical chemistry, cytokine levels
      and pharmacokinetics (PK). Safety assessments will be conducted. At discharge on Study Day 5,
      patients will be asked to return on Study Days 7, 10, and 15 for blood sampling and safety
      assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virological Log Reduction (Virological Endpoint)</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fever Reduction (Clinical Endpoint)</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety-Proportion of patients experiencing adverse events and serious adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of patients experiencing adverse events and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative NS1 and NS1 clearance</measure>
    <time_frame>14 days</time_frame>
    <description>NS1 non-structural protein 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>14 days</time_frame>
    <description>Leukocytes, platelets, hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Clearance of drug (L/hr)</measure>
    <time_frame>5 days</time_frame>
    <description>Clearance of drug (L/hr)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Dengue Fever</condition>
  <arm_group>
    <arm_group_label>Celgosivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celgosivir</intervention_name>
    <description>100 mg capsules, 400 mg loading dose 200 mg bid</description>
    <arm_group_label>Celgosivir</arm_group_label>
    <other_name>Bu-Cast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Capsules of identical appearance containing starch</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Fever of ≥ 38°C of ≤ 48 hr duration.

          -  At least two of the following criteria indicating probable dengue infection:

               -  Live or work in or recent travel to dengue endemic area

               -  Nausea and vomiting

               -  Presence of rash

               -  Aches and pains, including headache, or retro-orbital, muscle or joint pain

          -  Positive NS1 strip assay

        Main Exclusion Criteria:

          -  Clinical signs and symptoms for severe dengue

          -  Patients with certain abnormal laboratory values

          -  History of presently active intestinal disorders

          -  Severe diarrhea

          -  Current usage of anticoagulant drugs

          -  Other clinically significant acute illness

          -  History of severe drug and/or food allergies

          -  Exposure to investigational agent within 30 days prior to study drug administration

          -  Clinically significant abnormal physical exam unrelated to dengue fever

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subhash Vasudevan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Duke-NUS Graduate Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>November 28, 2013</last_update_submitted>
  <last_update_submitted_qc>November 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

